1-13 of 13
Kyle A Beckwith
Close
Save search
Sort by
Journal Articles

Utilizing Clinical Features of Progression to Predict Richter's Syndrome in Patients with CLL Progressing after Ibrutinib

Free
Adam S Kittai, Ying Huang, Ashleigh Keiter, Kyle A Beckwith, Daniel Goldstein, Seema A Bhat, David A. Bond, John C. Byrd, Michael R Grever, Kerry A Rogers, Jennifer A. Woyach
Journal: Blood
Blood (2021) 138 (Supplement 1): 3731.
https://doi.org/10.1182/blood-2021-144518
Published: 2021
Journal Articles

Increasing Karyotypic Complexity Predicts Outcomes in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Free
Daniel Goldstein, MD, Kyle A. Beckwith, MDPhD, Cecelia Miller, PhD, Ying Huang, MS, MA, Lynne V. Abruzzo, MD PhD, Seema A Bhat, MD, David A. Bond, MD, John C. Byrd, MD, Michael R. Grever, MD, Nyla A Heerema, PhD, Kerry A. Rogers, MD, Amy S. Ruppert, PhD, Jennifer A. Woyach, MD, Adam S. Kittai, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 2–3.
https://doi.org/10.1182/blood-2020-136714
Published: 2020
Journal Articles

Leukemic Cell Expressed CTLA-4 Suppresses T Cells Via Down-Modulation of CD80 By Trans-Endocytosis

Free
Priscilla Do, BS, Kyle A. Beckwith, PhD, Larry Beaver, Brittany G. Griffin, Xiaokui Mo, PhD MAS, Jeffrey Jones, MD MPH, Erin K. Hertlein, PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD
Journal: Blood
Blood (2016) 128 (22): 3221.
https://doi.org/10.1182/blood.V128.22.3221.3221
Published: 2016
Journal Articles

BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia and Lymphoma

Free
Deborah M Stephens, DO, Kyle A. Beckwith, PhD, Priscilla Do, BS, Carolyn Cheney, BS, Xiaokui Mo, PhD MAS, Karilyn Larkin, MD, Jeffrey Jones, MD MPH, Farrukh T. Awan, Laura Grosmaire, PhD, Randy Jones, PhD, Julie DiPaolo, PhD, Stacey Tannheimer, Karl-Heinz Heider, PhD, John C. Byrd, MD, Natarajan Muthusamy, DVM, PhD
Journal: Blood
Blood (2016) 128 (22): 2767.
https://doi.org/10.1182/blood.V128.22.2767.2767
Published: 2016
Journal Articles

Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism

Free
Meixiao Long, MD PhD, Kyle A. Beckwith, PhD, Priscilla Do, BS, Mundy L Bethany, PhD, Gordon Gordon, Amy M. Lehman, MAS, Kami J. Maddocks, MD, Carolyn Cheney, BS, Jeffrey Jones, MD MPH, Leslie A. Andritsos, MD, Farrukh T. Awan, Joseph A. Fraietta, PhD, Carl H June, MD, Marcela V. Maus, MDPhD, Jennifer A. Woyach, MD, Michael A. Caligiuri, MD, Amy J. Johnson, PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD
Journal: Blood
Blood (2016) 128 (22): 3238.
https://doi.org/10.1182/blood.V128.22.3238.3238
Published: 2016
Journal Articles

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

Free
Clinical Trials & Observations
Joseph A. Fraietta, Kyle A. Beckwith, Prachi R. Patel, Marco Ruella, Zhaohui Zheng, David M. Barrett, Simon F. Lacey, Jan Joseph Melenhorst, Shannon E. McGettigan, Danielle R. Cook, Changfeng Zhang, Jun Xu, Priscilla Do, Jessica Hulitt, Sagar B. Kudchodkar, Alexandria P. Cogdill, Saar Gill, David L. Porter, Jennifer A. Woyach, Meixiao Long, Amy J. Johnson, Kami Maddocks, Natarajan Muthusamy, Bruce L. Levine, Carl H. June, John C. Byrd, Marcela V. Maus
Journal: Blood
Blood (2016) 127 (9): 1117–1127.
https://doi.org/10.1182/blood-2015-11-679134
Published: 2016
Includes: Supplemental data
Journal Articles

The Role of Tetraspanin CD37 in B-Cell Malignancy

Free
Kyle A. Beckwith, BS, Erich I. Williams, BS, Mark D. Wright, PhD, Annemiek B. van Spriel, PhD, John C. Byrd, MD, Natarajan Muthusamy, DVM, PhD
Journal: Blood
Blood (2015) 126 (23): 1258.
https://doi.org/10.1182/blood.V126.23.1258.1258
Published: 2015
Journal Articles

Ibrutinib Treatment Reduces Both T-Regulatory Cells and B-Regulatory Cell Phenotype in Malignant B Cells in Chronic Lymphocytic Leukemia Patients

Free
Meixiao Long, MD PhD, Kyle A. Beckwith, BS, Kami J. Maddocks, MD, Carolyn Cheney, BS, Jennifer A. Woyach, MD, Amy J. Johnson, PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD
Journal: Blood
Blood (2015) 126 (23): 2940.
https://doi.org/10.1182/blood.V126.23.2940.2940
Published: 2015
Journal Articles

Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia

Free
Brief Report
Zachary A. Hing, Rose Mantel, Kyle A. Beckwith, Daphne Guinn, Erich Williams, Lisa L. Smith, Katie Williams, Amy J. Johnson, Amy M. Lehman, John C. Byrd, Jennifer A. Woyach, Rosa Lapalombella
Journal: Blood
Blood (2015) 125 (20): 3128–3132.
https://doi.org/10.1182/blood-2015-01-621391
Published: 2015
Includes: Supplemental data
Journal Articles

BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia

Free
Deborah M Stephens, DO, Kyle A Beckwith, B.S., Carolyn Cheney, B.S, Xiaokui Mo, PhD MAS, Joseph M Flynn, D.O., MPH, Jeffrey A. Jones, MD, Kami J. Maddocks, MD, Karl-Heinz Heider, PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD
Journal: Blood
Blood (2014) 124 (21): 4681.
https://doi.org/10.1182/blood.V124.21.4681.4681
Published: 2014
Journal Articles

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Free
Jason A. Dubovsky, Kyle A. Beckwith, Gayathri Natarajan, Jennifer A. Woyach, Samantha Jaglowski, Yiming Zhong, Joshua D. Hessler, Ta-Ming Liu, Betty Y. Chang, Karilyn M. Larkin, Matthew R. Stefanovski, Danielle L. Chappell, Frank W. Frissora, Lisa L. Smith, Kelly A. Smucker, Joseph M. Flynn, Jeffrey A. Jones, Leslie A. Andritsos, Kami Maddocks, Amy M. Lehman, Richard Furman, Jeff Sharman, Anjali Mishra, Michael A. Caligiuri, Abhay R. Satoskar, Joseph J. Buggy, Natarajan Muthusamy, Amy J. Johnson, John C. Byrd
Journal: Blood
Blood (2013) 122 (15): 2539–2549.
https://doi.org/10.1182/blood-2013-06-507947
Published: 2013
Includes: Supplemental data
Journal Articles

Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells

Free
Jason A Dubovsky, Ph.D, Kyle A Beckwith, B.S., Jennifer A. Woyach, MD, Samantha M. Jaglowski, MD, MPH, Joshua Hessler, Betty Y. Chang, PhD, Karilyn Larkin, Matthew R Stefanovski, B.S., Frank W Frissora, M.S., Lisa L. Smith, Kelly A Smucker, Joseph M. Flynn, DO, MPH, Jeffrey A. Jones, MD, MPH, Leslie A Andritsos, MD, Kami Maddocks, MD, Amy Lehman, Richard R. Furman, MD, Jeff Sharman, MD, Anjali Mishra, Ph.D., Michael A. Caligiuri, M.D., Joseph J. Buggy, PhD, Natarajan Muthusamy, DVM, Ph.D, Amy J Johnson, PhD, John C. Byrd, MD
Journal: Blood
Blood (2012) 120 (21): 775.
https://doi.org/10.1182/blood.V120.21.775.775
Published: 2012
Journal Articles

A Transgenic Mouse Model of Aggressive B-Cell Malignancy for Evaluating Anti-Human CD37 Therapeutics

Free
Kyle A Beckwith, B.S., Frank W Frissora, M.S., Matthew R Stefanovski, B.S., Jutta Deckert, Ph.D., Carlo M Croce, M.D., Xiaokui Mo, PhD, David Jarjoura, PhD, John C. Byrd, MD, Natarajan Muthusamy, DVM, Ph.D
Journal: Blood
Blood (2012) 120 (21): 188.
https://doi.org/10.1182/blood.V120.21.188.188
Published: 2012